Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) - Equities research analysts at Noble Financial issued their Q1 2026 earnings estimates for Gyre Therapeutics in a report issued on Tuesday, September 9th. Noble Financial analyst R. Leboyer expects that the company will post earnings per share of $0.12 for the quarter. Noble Financial also issued estimates for Gyre Therapeutics' Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.13 EPS and Q4 2026 earnings at $0.14 EPS.
Separately, HC Wainwright initiated coverage on shares of Gyre Therapeutics in a research report on Tuesday, August 26th. They set a "buy" rating and a $18.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $18.00.
Get Our Latest Stock Report on GYRE
Gyre Therapeutics Price Performance
Shares of NASDAQ GYRE traded up $0.06 during midday trading on Wednesday, reaching $7.89. 30,181 shares of the stock were exchanged, compared to its average volume of 159,002. The business has a 50-day simple moving average of $7.62 and a two-hundred day simple moving average of $8.55. The company has a market capitalization of $759.91 million, a price-to-earnings ratio of 789.79 and a beta of 1.86. Gyre Therapeutics has a 12 month low of $6.11 and a 12 month high of $19.00.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). Gyre Therapeutics had a net margin of 4.08% and a return on equity of 7.67%. The business had revenue of $26.77 million during the quarter, compared to the consensus estimate of $30.80 million.
Institutional Trading of Gyre Therapeutics
A number of hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its holdings in shares of Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock worth $46,000 after buying an additional 1,402 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company's stock worth $47,000 after buying an additional 2,961 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Gyre Therapeutics by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock worth $49,000 after buying an additional 913 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Gyre Therapeutics by 77.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company's stock worth $54,000 after buying an additional 3,244 shares during the period. Finally, Advantage Alpha Capital Partners LP boosted its holdings in shares of Gyre Therapeutics by 54.0% during the 1st quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company's stock worth $105,000 after buying an additional 4,790 shares during the period. 23.99% of the stock is owned by institutional investors and hedge funds.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Articles
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
